JP2023519974A5 - - Google Patents
Info
- Publication number
- JP2023519974A5 JP2023519974A5 JP2022559578A JP2022559578A JP2023519974A5 JP 2023519974 A5 JP2023519974 A5 JP 2023519974A5 JP 2022559578 A JP2022559578 A JP 2022559578A JP 2022559578 A JP2022559578 A JP 2022559578A JP 2023519974 A5 JP2023519974 A5 JP 2023519974A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- formula
- conjugate
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025096813A JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003179P | 2020-03-31 | 2020-03-31 | |
| US63/003,179 | 2020-03-31 | ||
| US202063067967P | 2020-08-20 | 2020-08-20 | |
| US63/067,967 | 2020-08-20 | ||
| PCT/IB2021/052713 WO2021198965A1 (en) | 2020-03-31 | 2021-03-31 | Neodegrader conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025096813A Division JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519974A JP2023519974A (ja) | 2023-05-15 |
| JP2023519974A5 true JP2023519974A5 (enExample) | 2024-01-11 |
Family
ID=77928113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559578A Pending JP2023519974A (ja) | 2020-03-31 | 2021-03-31 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
| JP2025096813A Pending JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025096813A Pending JP2025128284A (ja) | 2020-03-31 | 2025-06-10 | ｎｅｏＤｅｇｒａｄｅｒコンジュゲート |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230338564A1 (enExample) |
| EP (1) | EP4126067A4 (enExample) |
| JP (2) | JP2023519974A (enExample) |
| KR (1) | KR20230051120A (enExample) |
| CN (1) | CN115867322B (enExample) |
| AU (1) | AU2021249532A1 (enExample) |
| BR (1) | BR112022019532A2 (enExample) |
| CA (1) | CA3173118A1 (enExample) |
| IL (1) | IL296846A (enExample) |
| MX (1) | MX2022011825A (enExample) |
| WO (1) | WO2021198965A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7724394B2 (ja) * | 2019-10-09 | 2025-08-18 | モンテ ローザ セラピューティクス アーゲー | イソインドリノン化合物 |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| AU2022284372A1 (en) * | 2021-06-03 | 2023-12-14 | Bristol-Myers Squibb Company | Neodegrader-anti-cd33 antibody conjugates |
| US20250090681A1 (en) * | 2021-06-03 | 2025-03-20 | Orum Therapeutics, Inc. | Neodegrader conjugates |
| WO2023037268A1 (en) * | 2021-09-08 | 2023-03-16 | Orum Therapeutics, Inc. | Linkers for use in antibody drug conjugates |
| AU2023230346A1 (en) * | 2022-03-09 | 2024-10-17 | Orum Therapeutics, Inc. | Activators of effector t cells |
| EP4527415A1 (en) | 2022-05-18 | 2025-03-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| US20260131015A1 (en) * | 2022-10-06 | 2026-05-14 | Orum Therapeutics, Inc. | Neodegrader conjugates |
| KR20250133786A (ko) * | 2023-02-15 | 2025-09-08 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 도마이드계 분자 접착제 유도체 및 이의 용도 |
| WO2024187006A1 (en) * | 2023-03-08 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Bioorthogonal activation of protac prodrugs |
| LT4601703T (lt) | 2023-04-18 | 2026-06-25 | Astrazeneca Ab | Konjugatai, apimantys atskeliamuosius jungtukus |
| AU2024263367A1 (en) | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| KR20260023524A (ko) * | 2023-05-18 | 2026-02-20 | 파이어플라이 바이오, 인크. | 이소인돌리논-글루타르이미드 항체 접합체 및 이의 용도 |
| EP4512427A1 (en) * | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Antibody-drug conjugates based on molecular glue degraders and uses thereof |
| CN122249237A (zh) | 2023-11-14 | 2026-06-19 | 先声再明医药股份有限公司 | 配体-药物偶联物、偶联连接子及其用途 |
| WO2025168071A1 (zh) * | 2024-02-08 | 2025-08-14 | 映恩生物制药（苏州）有限公司 | 一种含氮杂环化合物、其偶联物及其制备方法和用途 |
| TW202613092A (zh) * | 2024-06-07 | 2026-04-01 | 大陸商上海齊魯製藥研究中心有限公司 | Gspt1降解劑抗體偶聯物 |
| WO2026007898A1 (zh) * | 2024-07-01 | 2026-01-08 | 上海海雁医药科技有限公司 | 含苯乙氧基亚烷基胺结构的异吲哚啉化合物、其药物组合物及应用 |
| WO2026032417A1 (zh) * | 2024-08-08 | 2026-02-12 | 石药集团巨石生物制药有限公司 | Gspt1降解剂和含有gspt1降解剂的抗体偶联物及其用途 |
| WO2026041050A1 (zh) * | 2024-08-20 | 2026-02-26 | 海思科医药集团股份有限公司 | 一种配体-蛋白降解剂偶联物及其在医药上的应用 |
| WO2026056955A1 (zh) * | 2024-09-11 | 2026-03-19 | 江苏恒瑞医药股份有限公司 | 配体-药物偶联物及其医药用途 |
| WO2026077418A1 (zh) * | 2024-10-11 | 2026-04-16 | 上海海雁医药科技有限公司 | 含苯乙氧基亚烷基胺结构的异吲哚啉化合物及其偶联物和用途 |
| WO2026092541A1 (zh) * | 2024-10-29 | 2026-05-07 | 苏州宜联生物医药有限公司 | 一种包含蛋白降解剂的药物连接体偶联物及其制备方法和用途 |
| CN121991160A (zh) * | 2024-11-08 | 2026-05-08 | 北京森妙生物科技有限公司 | 一种靶向蛋白降解剂及其药物组合物和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| CA2957226C (en) * | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| US8114621B2 (en) * | 2010-03-12 | 2012-02-14 | Saladax Biomedical Inc. | Lenalidomide and thalidomide immunoassays |
| ES2843973T3 (es) * | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| EP3229844B1 (en) * | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
| AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| CN119405833A (zh) * | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
-
2021
- 2021-03-31 US US17/995,006 patent/US20230338564A1/en active Pending
- 2021-03-31 JP JP2022559578A patent/JP2023519974A/ja active Pending
- 2021-03-31 AU AU2021249532A patent/AU2021249532A1/en active Pending
- 2021-03-31 BR BR112022019532A patent/BR112022019532A2/pt unknown
- 2021-03-31 CA CA3173118A patent/CA3173118A1/en active Pending
- 2021-03-31 KR KR1020227037931A patent/KR20230051120A/ko active Pending
- 2021-03-31 MX MX2022011825A patent/MX2022011825A/es unknown
- 2021-03-31 WO PCT/IB2021/052713 patent/WO2021198965A1/en not_active Ceased
- 2021-03-31 IL IL296846A patent/IL296846A/en unknown
- 2021-03-31 EP EP21779309.0A patent/EP4126067A4/en active Pending
- 2021-03-31 CN CN202180025882.5A patent/CN115867322B/zh active Active
-
2025
- 2025-06-10 JP JP2025096813A patent/JP2025128284A/ja active Pending